Pfizer eyes Covid vaccine for all variants before 2023
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Tuesday
July 05, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
TUESDAY, JULY 05, 2022
Pfizer eyes Covid vaccine for all variants before 2023

Coronavirus chronicle

BSS/AFP
14 April, 2022, 10:45 am
Last modified: 14 April, 2022, 10:51 am

Related News

  • BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • Children aged 5-12 yrs to get Pfizer vaccine 
  • US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • Pfizer says 3 Covid shots protect children under 5
  • Cash-rich Pfizer to pay $11.6 bln for Biohaven in biggest deal since 2016

Pfizer eyes Covid vaccine for all variants before 2023

BSS/AFP
14 April, 2022, 10:45 am
Last modified: 14 April, 2022, 10:51 am
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo

A Covid-19 vaccine effective against multiple variants is possible before the end of 2022, the head of US pharmaceutical giant Pfizer said Wednesday.

Chairman Albert Bourla said the firm was also working on producing a vaccine that could provide good protection for a whole year, meaning people would come back annually for boosters, as with influenza shots.

"I hope, clearly by autumn... that we could have a vaccine" that worked against not only the dominant Omicron but all known variants, he said.

"It is a possibility that we have it by then. It is not a certainty," he told a media briefing organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) big pharma lobby group.

The Pfizer-BioNTech vaccine is one of the most effective against Covid-19.

Though, like other jabs, it has seen waning effectiveness against the now-dominant Omicron variant of the virus, it still offers strong protection against serious disease, hospitalisation and death.

IFPMA director general Thomas Cueni said the world had to learn to live with the virus that causes Covid-19 disease, saying: "We are beyond the time when you can eradicate SARS-CoV-2."

Bourla said there was a risk of vaccine fatigue, predicting that few people who have so far declined the chance to be vaccinated would change their minds, and suggesting that fewer people would come back for fourth doses than came forward for a third, booster dose.

"What the world really needs is a vaccine that will last a year. I think this is what will become the optimal public health solution," he said.

"It's way more easy to be administered and have the population be compliant with that.

"It is very challenging, technically, to do it with this virus -- but we are working on it."

IP waiver plan blasted

The World Health Organization is aware of 153 Covid-19 vaccines that have been in clinical development -- tested on humans -- and 196 in pre-clinical development.

But so far, the UN health agency has only authorised eight vaccines and versions thereof: those made by Pfizer-BioNTech, AstraZeneca, Janssen, Moderna, Sinovac, Sinopharm, Bharat Biotech and Novavax.

The IFPMA briefing condemned suggestions that intellectual property rights on Covid-19 vaccines should be temporarily lifted during the pandemic, in a bid to increase production.

"I'm stunned that the proposed IP waiver is still debated while supplies are far outstripping demand," said Cueni.

With more than a billion vaccine doses being produced every month, Eli Lilly chairman David Ricks called it "a solution looking for a problem", while Bourla branded the idea "insane".

In a later WHO press conference, the UN health agency's chief scientist Soumya Swaminathan said the vaccine supply situation had dramatically improved in recent months.

The problem, she said, was more one of logistics and getting doses into arms in countries, especially in Africa, where only 13 percent have been fully jabbed.

"We are able to now supply as many doses as countries want, on demand, to them. The issue now really is on delivery," she said.

Top News / World+Biz

Pfizer / Pfizer Inc / Pfizer Covid-19 Vaccine / Pfizer coronavirus vaccine / Pfizer COVID vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Padma Bridge opens up investment spree in south
    Padma Bridge opens up investment spree in south
  • BB slaps 100% LC margin to discourage imports of cars, electronics among other items 
    BB slaps 100% LC margin to discourage imports of cars, electronics among other items 
  • Several law enforcement departments monitor the scene of a mass shooting at a Fourth of July parade route in the wealthy Chicago suburb of Highland Park, Illinois, US July 4, 2022. REUTERS/Max Herman
    Suspect captured in shooting at 4 July parade in Chicago's Highland Park suburb

MOST VIEWED

  • A man helps his son to wear mask at Covid-19 test centre at KSRTC bus stand in Bengaluru.(PTI)
    India records 16,103 new Covid cases, 31 deaths in 24 hours
  • Former North Korean defectors living in South Korea, release balloons containing one dollar banknotes, radios, CDs and leaflets denouncing the North Korean regime, towards the north near the demilitarized zone which separates the two Koreas in Paju, north of Seoul January 15, 2014. REUTERS/Kim Hong-Ji/File Photo
    North Korea blames 'alien things' near border with South for Covid outbreak
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. Reuters: llustration
    BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    S Korea approves first domestically developed Covid vaccine
  • Photo: Collected
    US medical experts call for Omicron-specific Covid boosters

Related News

  • BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • Children aged 5-12 yrs to get Pfizer vaccine 
  • US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • Pfizer says 3 Covid shots protect children under 5
  • Cash-rich Pfizer to pay $11.6 bln for Biohaven in biggest deal since 2016

Features

Last month Swapan Kumar Biswas, the acting principal of Mirzapur United College, was forced to wear a garland of shoes for ‘hurting religious sentiments.’ Photo: Collected

Where do teachers rank in our society?

21h | Panorama
Japanese Ambassador Naoki Ito. Sketch: TBS

'The game-changing projects are in line with the Bay of Bengal Industrial Growth Belt initiative'

23h | Panorama
A Glittery Eid

A Glittery Eid

1d | Mode
Rise’s target customers are people who crave to express themselves through what they wear, and their clothing line is not relegated to any age range.

Level up your Eid game with Rise

1d | Mode

More Videos from TBS

Realme Narzo 50A Prime available now

Realme Narzo 50A Prime available now

11h | Videos
Export products to get diversified

Export products to get diversified

13h | Videos
Horrible routes of human trafficking

Horrible routes of human trafficking

14h | Videos
Why Mbappe cheated Real Madrid

Why Mbappe cheated Real Madrid

14h | Videos

Most Read

1
TBS Illustration
Education

Universities may launch online classes again after Eid

2
Meet the man behind 'Azke amar mon balo nei'
Splash

Meet the man behind 'Azke amar mon balo nei'

3
Padma Bridge from satellite. Photo: Screengrab
Bangladesh

Padma Bridge from satellite 

4
World Bank to give Bangladesh $18b IDA loans in next five years
Economy

World Bank to give Bangladesh $18b IDA loans in next five years

5
Illustration: TBS
Interviews

‘No Bangladeshi company has the business model for exporting agricultural product’

6
Lee Hyun-seung (third from right), head of Korea Expressway Corp.'s Overseas Project Division, shakes hands with Quazi Muhammad Ferdous, head of the Bridge Authority of Bangladesh, after signing a contract on June 29 (local time).
Bangladesh

Korean company to oversee N8 Expressway in Bangladesh

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
Workers ready a passenger vessel with a fresh coat of paint to the deck ahead of the Eid-ul-Azha at a dockyard at Mirerbagh in South Keraniganj. The vessel getting the makeover plies the Bhandaria route and will take holidaying people from the city to their country homes. Eid will be celebrated on 10 June this year. The photo was taken on Monday. Photo: Mumit M

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net